Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Valganciclovir
Drug ID BADD_D02326
Description Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Indications and Usage Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.
Marketing Status approved; investigational
ATC Code J05AB14
DrugBank ID DB01610
KEGG ID D02495
MeSH ID D000077562
PubChem ID 135413535
TTD Drug ID D06GWF
NDC Product Code 69097-277; 31722-832; 50268-787; 60429-846; 70069-810; 71921-210; 27241-158; 55111-762; 61269-480; 0004-0038; 70010-051; 0904-6796; 63739-076; 68084-965; 71151-003
UNII GCU97FKN3R
Synonyms Valganciclovir | Ganciclovir L-valyl Ester | Ganciclovir L valyl Ester | Valcyt | Valganciclovir Hydrochloride | Valcyte
Chemical Information
Molecular Formula C14H22N6O5
CAS Registry Number 175865-60-8
SMILES CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Infertility21.03.02.001--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.001--Not Available
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Localised infection11.01.08.006--Not Available
Lymphadenopathy01.09.01.002--Not Available
Macular oedema06.04.06.005--Not Available
Malaise08.01.01.003--
Mental disability26.01.01.001--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myasthenic syndrome17.05.04.004; 15.05.08.003; 16.32.01.002; 10.04.05.005--Not Available
Myoclonus17.02.05.008--Not Available
Nasal congestion22.04.04.001--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neoplasm16.16.02.001--Not Available
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neutropenia01.02.03.004--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages